Clinilabs
Business Services · New Jersey, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
4 Industrial Way W, Eatontown, New Jerse...Phone Number
(646) 215-6400Website
www.clinilabs.comRevenue
$31 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
2
1
1
About Clinilabs
Clinilabs Drug Development Corporation is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system ("CNS") drug development. With deep expertise in CNS, we are committed to the development of medicines that treat a range of psychiatric, neurological and substance use disorders, as well as rare and ultra-rare CNS diseases. Clinilabs partners with pharmaceutical and biotechnology companies to deliver a complete, first-in-human to Phase 3 spectrum of high quality, timely, and cost-effective clinical drug development services, with the shared goal of speeding new CNS medicines to market. We are process-driven yet structured to be nimble, providing personalized service that meets the needs of customers and projects of all sizes. Clinilabs has conducted more than 700 CNS clinical trials in our 23-year history and played a pivotal role in the approval of 19 new therapies across 10 CNS indications to help transform the lives of patients wRead more
Clinilabs Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Clinilabs your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if Clinilabs has recently received funding, and reach out quickly before it becomes old news!
Check out if Clinilabs is spiking on competitors!
Product Launch: Get notified when Clinilabs launches new products
Click to see if Clinilabs had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Clinilabs has new funding data
Earning: See what the market has to say on Clinilabs recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Clinilabs, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Clinilabs
Recommended Actions
Reach out to Masked Content who joined Clinilabs as Masked Content
Find more new buyers
Compare Similar Companies to Clinilabs
Compare insights from companies similar to Clinilabs, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Clinilabs
$31M
51-200
Private
<$5M
2000
AS
Agustina SalomoneAP Accounting Processor & Chief Revenue Officer, Clinical Research
Company Profile Activity
Activity Insights
Clinilabs is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Clinilabs is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Clinilabs.
Clinilabs financials insights
Gather financial insights about Clinilabs, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Debt
$2M
2021
Debt
$2M
Clinilabs Tech Stack
A closer look at the technologies used by Clinilabs
Most Recent Scoops
Open Position
Open Position
Open Position
Person-Based
Compliance
Open Position
Clinilabs News & Media
InTandem Capital Partners Announces Strategic Investment in Clinilabs
NEW YORK--(BUSINESS WIRE)--InTandem Capital Partners (“InTandem Capital” or the “Firm”), a healthcare services-focused private equity firm, announced today that it has partnered with the founder and management team at Clinilabs (the “Company”), a global, full-service contract research organization (CRO) dedicated to providing a complete range of central nervous system (CNS) drug and device development services to the pharmaceutical, biotechnology, and medical technology industries. Since the CoBREAKING: Cybin And Clinilabs Receive DEA License For First-In-Human Clinical Trial Of Psilocybin To Treat Depression
Cybin Inc. (NEO: CYBN) (NYSE: CYBN) and Clinilabs Drug Development Corporation (Clinilabs) announced that the U.S. read moreCybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, and its partner Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced that the U.S. Drug Enforcement Agency (“DEA”) has granted a Schedule I license to support the first-in-human PhaseClinilabs Drug Development Corporation Begins Enrollment for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder
EATONTOWN, N.J.--(BUSINESS WIRE)--Clinilabs Drug Development Corporation (“Clinilabs”), a global, full-service contract research organization with deep expertise in central nervous system drug development, announced today that enrollment has begun in a Phase 1/2a clinical trial of CYB003, the first novel psilocybin analog to be evaluated in Phase 1/2a development for the treatment of major depressive disorder (“MDD”). CYB003 is being developed by Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cyb
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Clinilabs
Sign Up For FreeTo access detailed company insights
Clinilabs Drug Development Corporation is the only global, full-service contract research organization (CRO) focused exclusively on central nervous system ("CNS") drug development. With deep expertise in CNS, we are committed to the development of medicines that treat a range of psychiatric, neurological and substance use disorders, as well as rare... Read More
